Results 31 to 40 of about 4,414 (225)

COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD

open access: yesФармакоэкономика, 2017
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide).
E. G. Kosolapov   +5 more
doaj   +1 more source

A broad-spectrum pneumococcal vaccine induces mucosal immunity and protects against lethal Streptococcus pneumoniae challenge

open access: yesEmerging Microbes and Infections, 2023
Pneumococcal disease is a major threat to public health globally, impacting individuals across all age groups, particularly infants and elderly individuals.
Fang-Feng Chiu   +6 more
doaj   +1 more source

Left Atrial Appendage Closure for Atrial Fibrillation in the Elderly >75 Years Old: A Meta-Analysis of Observational Studies

open access: yesDiagnostics, 2022
Background: Left atrial appendage closure (LAAC) is an established therapy for patients with atrial fibrillation (AF); however, there is a limited understanding of LAAC in elderly patients (≥75 years old).
Shaojie Han   +5 more
doaj   +1 more source

DNA methylation governs the dynamic regulation of inflammation by apoptotic cells during efferocytosis [PDF]

open access: yes, 2017
Efficient clearance of apoptotic cells (AC) is pivotal in preventing autoimmunity and is a potent immunosuppressive stimulus. However, activation of cells prior to apoptosis abolishes their immunoregulatory properties.
Brown, MA   +4 more
core   +1 more source

COST-EFFECTIVENESS OF VILANEROL / UMECLIDINIUM VERSUS TIOTROPIUM IN SEVERE AND VERY SEVERE COPD

open access: yesФармакоэкономика, 2017
In accordance with currently accepted recommendations for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), both monotherapy with long-acting anticholinergics (LAAC) or combined therapy (LAAC / long-acting beta-agonists, LABA ...
E. G. Kosolapov   +3 more
doaj   +1 more source

Percutaneous Retrieval of Left Atrial Appendage Closure Devices in Patients With Atrial Fibrillation: A Case Report

open access: yesFrontiers in Cardiovascular Medicine, 2022
Left atrial appendage closure (LAAC) devices can be inadvertently released into unfavorable locations, which may allow them to migrate to a different position within the left atrial appendage or embolize from the heart into the aorta.
Saihua Wang   +5 more
doaj   +1 more source

Cost‐Effectiveness of Left Atrial Appendage Closure for Stroke Reduction in Atrial Fibrillation: Analysis of Pooled, 5‐Year, Long‐Term Data

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2019
Background Recent publications reached conflicting conclusions about the cost‐effectiveness of left atrial appendage closure (LAAC) with the Watchman device (Boston Scientific, Marlborough, MA) for stroke risk reduction in nonvalvular atrial fibrillation
Vivek Y. Reddy   +4 more
doaj   +1 more source

La puerta califal del castillo de Gormaz

open access: yesArqueología de la Arquitectura, 2008
Este artículo aborda el análisis parcial de un monumento emblemático de la arquitectura militar andalusí, muy citado como ejemplo de la arquitectura califal pero que aún hoy adolece de un estudio en profundidad y con metodología adecuada para identificar
Antonio Almagro
doaj   +1 more source

Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta‐Analysis

open access: yesJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Percutaneous left atrial appendage closure (LAAC) has been suggested as an alternative to long‐term oral anticoagulation for nonvalvular atrial fibrillation, but comparative data remain scarce. We aimed to assess ischemic and bleeding outcomes
Angelo Oliva   +15 more
doaj   +1 more source

Home - About - Disclaimer - Privacy